What peptide therapy really costs in 2026
Last updated: November 4, 2026 · 10 min read · By the Grey Peptides Editorial Board
- Branded GLP-1 drugs are the peptide therapies whose makers publish a cash price. On October 2 and again on October 27, 2026, self-pay prices for Zepbound, Wegovy and Foundayo ran from $149 to $449 a fill with on-time refills, and up to $699 when a Zepbound refill is late.
- At those prices, a first year of Zepbound bought for cash costs about $5,637 if every refill is on time, before doctor visits and supplies. Several of today's lower prices are only promised through December 31, 2026.
- Compounded copies of semaglutide and tirzepatide were the cheap option while both drugs were in shortage. FDA declared both shortages over by February 2025, and its decision on the narrower question still open had not been published in the Federal Register as of October 27, 2026.
- Clinic peptides such as BPC-157 have no audited prices and, as of October 27, 2026, no recognised route to legal compounding: FDA lists BPC-157's Category 2 nomination as withdrawn, but it is not in Category 1 and not on the 503A list.
The short answer
"Peptide therapy" covers three different things, and their prices cannot be compared directly. Branded GLP-1 drugs are approved medicines whose makers publish what they charge people paying cash. Compounded drugs are versions made by pharmacies, which were legal on a large scale only while the branded drugs were in shortage. Clinic peptides such as BPC-157 are compounds that no regulator has approved, sold in programmes whose prices nobody audits.
As of October 27, 2026, the published cash prices for Zepbound, Wegovy and Foundayo run from $149 to $449 a fill when refills are on time 123. The other two pathways have no prices anyone verifies, and their legal footing has changed more than their advertising suggests.
Branded GLP-1s: the only prices anyone publishes
Lilly and Novo Nordisk both sell their weight-loss drugs directly to people paying cash, at prices set by dose. These are the figures on their own pages, read on October 2 and unchanged when re-read on October 27, 2026 132:
| Drug | Form | Self-pay price per fill | A fill is | Conditions |
|---|---|---|---|---|
| Zepbound (tirzepatide) High | Vial or KwikPen | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) | 28 days | $449 needs a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10 to 15 mg). Re-read October 27, 2026 |
| Wegovy (semaglutide) High | Pen | $199 for the first two fills (0.25 and 0.5 mg), then $349; $399 for Wegovy HD 7.2 mg | One month (a box of 4 pens) | The $199 introductory offer is for patients new to the Wegovy savings offer or NovoCare home delivery and runs through December 31, 2026. Re-read October 27, 2026 |
| Wegovy (semaglutide) | Pill | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) | One month (30 tablets) | No extra conditions stated. Re-read October 27, 2026 |
| Foundayo (orforglipron) Medium | Pill | $149 (0.8 and 2.5 mg), $199 (5.5 mg), $299 (9, 14.5 and 17.2 mg) | 30 days | 2.5 and 5.5 mg prices are temporary, through December 31, 2026; the top two doses need a refill within 45 days. Re-read October 27, 2026 |
Three details change what these numbers mean. First, a "month" is not the same everywhere: Lilly defines a Zepbound month as 28 days, so a year has 13 fills, while a Foundayo month is 30 days 12. Second, the Zepbound vial and KwikPen need syringes or pen needles bought separately 1. Third, the lowest prices come with conditions: Zepbound's and Foundayo's top-dose prices depend on refilling within 45 days, and Foundayo's 2.5 mg and 5.5 mg prices, like Wegovy's introductory offer, are only promised through December 31, 2026 123.
All of these are self-pay prices. With commercial insurance that covers the drug, each maker's savings card can bring the cost down to as little as $25 a month; Novo Nordisk caps Wegovy's card at $100 of savings a month, and Lilly's cards exclude anyone on a government plan such as Medicare or Medicaid 31. For eligible Medicare Part D members, CMS runs the Medicare GLP-1 Bridge from July 1, 2026 to December 31, 2027, with a $50 payment for certain GLP-1 drugs, and Lilly points Zepbound KwikPen and Foundayo patients to it 412. Our encyclopedia grades the evidence for tirzepatide, semaglutide and orforglipron on their own pages.
What a first year costs at today's prices
A monthly price hides the number most people need, which is the cost of a year. Zepbound's label starts at 2.5 mg and raises the dose in 2.5 mg steps after at least four weeks, and Lilly prices every dose from 7.5 mg up at the same $449 1. At the prices on Lilly's page on October 27, 2026, someone who buys 13 four-week fills for cash in a year, one at 2.5 mg, one at 5 mg and eleven at 7.5 mg or higher, pays $299 + $399 + (11 × $449) = $5,637, provided every refill lands within 45 days.
One late refill at 10 mg or above costs $699 instead of $449, an extra $250 for that fill 1. Someone who stays at 5 mg pays $299 + (12 × $399) = $5,087. None of these totals includes the prescriber's fees, any lab tests, or the syringes and needles. And the arithmetic only holds as long as the prices do, which for some offers is only promised to the end of 2026.
Compounded GLP-1s: the cheap option was tied to a shortage
From 2022, pharmacies and outsourcing facilities made copies of semaglutide and tirzepatide on a large scale, because both drugs were on FDA's shortage list and the law allows copies of drugs in shortage. FDA declared the tirzepatide shortage resolved in October 2024, a decision it reaffirmed that December, and the semaglutide shortage resolved on February 21, 2025 5. With the shortages over, the main legal basis for routine copies went with them.
A narrower question is still open: whether outsourcing facilities may use GLP-1 ingredients in bulk because of a clinical need. FDA's docket on it, FDA-2018-N-3240, closed to comments on July 30, 2026, and the newest document in it is still a notice from June 26, 2026. As of October 27, 2026, no final decision has been published 65. Our GLP-1 transition hub tracks that docket and what each outcome would mean.
We found no independent survey of compounded GLP-1 prices in PubMed, so we give no figures for them. A price from a seller tells you what that seller charges, not what the product is.
Clinic peptides: advertised prices and an unresolved legal status
The peptides that clinics and telehealth companies sell as "recovery" or "longevity" therapy are a different category. BPC-157 Low is not approved anywhere, and our encyclopedia grades its human evidence as low. Sermorelin Medium was once FDA-approved (as Geref) and is listed there as discontinued; ipamorelin Medium and CJC-1295 Medium were never approved. None is an approved, marketed drug today 7.
Their legal position is easy to misread. According to a law-firm report, FDA gave notice on April 15, 2026 that it would take BPC-157 and eleven other peptides out of Category 2, its list of bulk substances that raise significant safety concerns, after seven days 8; FDA's Category 2 page (content current as of April 22, 2026) now lists BPC-157 among nominations withdrawn by the nominators, without a date 9. FDA did not move them to Category 1, where compounding is tolerated while FDA evaluates them 8. FDA's category list, last updated May 14, 2026, does not name BPC-157 in any of its three categories 10. On July 23, FDA's compounding advisory committee voted 8 to 6 to recommend BPC-157 for the 503A list, against the recommendation of FDA's own staff, as reported by law firms (FDA has posted no tallies) 11 12, but a vote is advice, not a rule. As of October 27, 2026, no Federal Register document on 503A bulk drug substances has been published since September 20, 2026, and none has added BPC-157 or any other peptide to that list 13. The July votes did not change what pharmacies may lawfully do; our regulatory tracker follows each compound.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157, TB-500, MOTS-c, KPV, semax and epitalon under the forms, routes and conditions in its Appendix B 14. The policy is non-binding, labelled a draft and open to revision; FDA has not added any of them to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
Prices are just as murky. The pages that publish monthly figures for BPC-157 and similar peptides are clinics, telehealth companies and referral sites that sell or earn from these programmes; their figures are not audited, and because they sell the product we neither name them nor repeat their numbers.
When a clinic quotes a price, it is usually paying for some mix of five things: the first consultation, lab tests, follow-up visits, the product, and supplies. Asking which of those the price includes, and where the product is made, tells you more than the headline number.
What insurance and Medicare will pay for
Coverage follows approval. Zepbound, Wegovy and Foundayo are approved drugs, so plans can cover them, and the savings cards above fill some of the gap for people whose commercial plans do 123. Medicare Part D members can check their eligibility for the Medicare GLP-1 Bridge, which CMS has extended through December 31, 2027 so that it can collect more data before a possible BALANCE Model in Part D 4. Lilly lists its Zepbound and Foundayo options as eligible for health savings and flexible spending accounts, depending on the plan 12.
Clinic peptides are a different matter. A compound with no approval has no approved use for an insurer to cover, so programmes built on BPC-157 and its relatives are paid for out of pocket.
Why the cheapest offer is usually the most expensive
The lowest prices online tend to belong to products made outside any regulated supply chain. One study shows what that can mean. Researchers mapped the online market for semaglutide sold without a prescription, then placed test orders with six illegal online pharmacies offering it at the lowest prices 15. None of the three orders for Ozempic pens arrived, and the researchers counted them as non-delivery scams. The three vials that did arrive were all judged probable substandard or falsified products: they held more semaglutide than labelled, yet semaglutide made up only 7.7% to 14.4% of the powder in each vial, against sellers' claims of at least 99% purity, a different measure, and endotoxin was measured at 8.95 EU/mg in one vial, and the other two were reported only as below 2.9 and 2.2 EU/mg 15.
Products labelled "research use only" carry their own warning in the name: the label does not claim they are made or tested for people. A low price for something you cannot verify is not a saving.
Running your own numbers
Four checks turn a quoted price into a real one. Count fills, not months, because a 28-day fill means 13 purchases a year. Note the refill window, because missing it can add hundreds of dollars to a single fill. Add the costs outside the price: visits, labs, needles and syringes. And check the end date on any offer, because several of today's lowest prices are only promised through December 31, 2026.
Our cost calculator works out per-dose, per-month and per-cycle costs from a price you enter, including what is lost when a vial is mixed. It does the arithmetic; the prices still have to come from a source you can check.
Frequently asked questions
How much does peptide therapy cost in 2026?
It depends on the pathway. Branded GLP-1 drugs cost $149 to $449 a fill for cash with on-time refills, according to their makers' pages on October 27, 2026. Clinic peptide programmes publish their own figures, none of them audited.
How much does Zepbound cost without insurance?
On Lilly's LillyDirect page, re-read October 27, 2026: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg per 28-day fill, if you refill within 45 days. A late refill costs $499 at 7.5 mg and $699 at 10 to 15 mg.
Is compounded semaglutide still available?
FDA declared the semaglutide shortage resolved on February 21, 2025, which ended the main legal basis for routine copies. Whether outsourcing facilities may use GLP-1 ingredients in bulk was still undecided in the Federal Register as of October 27, 2026.
Is BPC-157 legal to compound now?
Not on the record as of October 27, 2026. FDA lists its Category 2 nomination as withdrawn but did not place it in Category 1, and although an advisory committee recommended it for the 503A list in July, no document has added it.
Does insurance cover peptide therapy?
Plans can cover approved drugs such as Zepbound, Wegovy and Foundayo, and savings cards can bring the cost down to as little as $25 a month for people with covering commercial plans. Unapproved clinic peptides are paid for out of pocket.
Related on Grey Peptides
- The compounded-GLP-1 transition
- Peptide cost calculator
- What the July 2026 PCAC votes did and didn't change
- Semaglutide vs tirzepatide
- What research use only really means
Sources
- Eli Lilly and Company. Zepbound on LillyDirect (lilly.com/lillydirect/zepbound), self-pay prices and terms (28-day month; regular prices if not refilled within 45 days); page modified September 2, 2026; read October 2 and October 27, 2026. Cited without a link.
- Eli Lilly and Company. Foundayo on LillyDirect (lilly.com/lillydirect/foundayo), self-pay prices and terms (30-day month); page modified September 18, 2026; read October 2 and October 27, 2026. Cited without a link.
- Novo Nordisk. Wegovy pricing on NovoCare Pharmacy (novocare.com/pharmacy/wegovy.html), no page date shown; read October 2 and October 27, 2026. Cited without a link.
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge): July 1, 2026 to December 31, 2027, $50 for eligible Part D beneficiaries, extended to collect data before a possible BALANCE Model in Part D; page last modified July 13, 2026; read October 27, 2026. BALANCE Model page last modified September 29, 2026, read October 2, 2026.
- Grey Peptides. The compounded-GLP-1 transition (/glp1-transition/): FDA shortage decisions and docket record from primary sources, last re-read September 25, 2026.
- Federal Register API: documents in docket FDA-2018-N-3240; newest is document 2026-12937, published June 26, 2026; queried October 2 and October 27, 2026.
- Grey Peptides encyclopedia entries for sermorelin (FDA-approved as Geref, discontinued), ipamorelin and CJC-1295 (never approved). Read October 27, 2026.
- Orrick, Herrington & Sutcliffe. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings, April 16, 2026: FDA gave notice on April 15 that 'after 7 days, it will remove 12 peptide bulk drug substances from Category 2', nominations 'withdrawn by the nominators'; removal does not by itself place them on the 503A list or in Category 1. Read October 27, 2026. Cited without a link.
- US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: 'Bulk drug substances nominated but withdrawn' (17 substances, including BPC-157, KPV, MOTS-c, epitalon, semax, emideltide, melanotan II, cathelicidin LL-37, GHK-Cu for injectable routes, dihexa acetate, PEG-MGF and TB-500); content current as of April 22, 2026; read October 27, 2026. No withdrawal or removal date is given. FDA
- US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (category list), updated May 14, 2026; read October 2 and October 27, 2026.
- McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
- Grey Peptides. The July 2026 PCAC votes (/news/pcac-july-2026-votes/), September 25, 2026, from FDA's meeting materials and published meeting reports; FDA has posted no tallies.
- Federal Register API: search for FDA documents matching '503A bulk' published since September 20, 2026, none found; queried October 2 and October 27, 2026.
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- Ashraf, A. R., Mackey, T. K., Vida, R. G., et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, 26, e65440. PMID: 39509151
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead